Professional-grade valuation for GLP-1 Biochemical Injuries. Analyze settlement trajectories using MDL 3094 court records and forensic multipliers.
MDL Active Cases
1250+
MDL 3094 Docket
FDA FAERS Volume
15,400+
GLP-1 Adverse Events
Presiding Judge
Marston, K.
Eastern Dist PA
NAION Delta
+700%
Vision Loss Risk
Semaglutide (Ozempic/Wegovy) operates as a GLP-1 receptor agonist, primarily designed to augment insulin secretion. However, for a high-risk cohort, this pharmacological "deceleration" triggers persistent **Gastric Paralysis**.
In 2026, the liability pivot shifted from the side effect itself to the **Failure to Warn** concerning permanent autonomic dysfunction. Documentation of scintigraphy (GES) latency is now the absolute anchor for Tier 1 compensation.
The weighted impact of multi-year exposure on gastric nerve pathways.
Cases originating before the Sept 2023 FDA label update carry punitive weight.
GES, Laparotomy, and NAION clinical markers as primary valuation triggers.
"MDL 3094 data indicates that represented claimants secure 3.5x higher points-based awards than those filing pro-se claims."
The Eastern District of Pennsylvania utilizes a point-weighted injury hierarchy for global resolution.
Permanent vision loss (NAION) or gastric paralysis requiring electrical stimulation/G-Tube. projected in the $500k-$1.2M range.
Bowel obstructions (Ileus) requiring surgical intervention (Laparotomy). Projected $250k-$550k.
Documented 4-hour gastric retention confirmed by scintigraphy without surgical correction. $100k-$250k.
Forensic Biochemical Simulation
GLP-1 receptor agonist accumulation study. Analyzing the biochemical timeline from first injection to autonomic nerve failure.
Analysis of internal Novo Nordisk safety alerts vs Public FDA labels. Pinpointing the 'Knowledge Window' before 2023.
Calculation of medical liens, future surgical costs, and earning capacity reduction due to chronic GI impairment.
MDL 3094 weights claims based on 4-hour Gastric Emptying Study (GES) results. Retention rates exceeding 20% at 4 hours trigger Tier 2 multipliers, while surgical requirements for pacing move the claim to Tier 1.
NAION (Non-Arteritic Anterior Ischemic Optic Neuropathy) causes sudden, permanent vision loss. Because of the catastrophic nature of blindness, these claims bypass standard GI tiers and are valued up to $1.5M in settlement projections.
Yes. The legal theory focuses on the drug's safety profile and labeling failures, not whether it was used for Type 2 Diabetes vs. obesity. Both Ozempic and Wegovy are part of the consolidated GLP-1 litigation.
Access the 2026 S-Class Actuarial Matrix. Calculate your Ozempic settlement point-score without personal ID.
Start Audit Engine